I follow the Bakers also. Their history of "astute" investment decisions is a large part of why I'm so heavily invested in Genomic Health. But you have to admit it is a little strange that this year there are no other insider purchases; only sales. (I'm going on recollection - please correct me if I'm wrong.) I've spent the past year trying to figure out why. For the most part the amounts sold have been piddling sums. Still, those sums represent large percentages of holdings for most directors. It is only the founders who still have huge stakes.
I wonder if they have been asked to auto sale to help keep the price low for the Bakers... I wonder if they have been promised a nice award shortly before sale or the taking of the company private. Any ideas?
I don't worry about too much downside with Genomic Health. I do worry, however, the upside is limited with the Bakers owning such a huge percentage. I will be very disappointed if they take it private. The buy back only increases their perentage.